Product model DFO-VET-API-25 is deferoxamine mesylate, a veterinary-grade active pharmaceutical ingredient supplied as a white to off-white powder or sterile low-endotoxin powder. The molecular formula is C₂₅H₄₈N₆O₈·CH₄O₃S, and the molecular weight is 656.79 g/mol. The compound is a hexadentate siderophore-derived iron chelator obtained by controlled fermentation of selected actinomycete strains, then purified to compendial identity. Oral solid-dosage forms are used primarily for intraluminal binding of ingested iron, while injectable presentations provide systemic chelation after subcutaneous, intramuscular, or intravenous administration. This division is necessary because the free ligand has low oral bioavailability; tablets, capsules, powders, granules, and premix presentations therefore address gastrointestinal iron exposure, not systemic burden.

Supplier model suffixes identify the physical form: DFO-VET-API-MF is a micronized low-moisture powder for tablets and capsules, DFO-VET-API-GF is a granular free-flowing grade for premix and granules, and DFO-VET-API-SL is a sterile low-endotoxin grade for injectable solutions. These model suffixes are not substitutes for batch release testing; each lot is supplied with a certificate of analysis referencing the relevant pharmacopoeial and VICH standards.

What Specification Parameters Govern Batch Release for Veterinary Deferoxamine API?

Release of the API follows a specification matrix combining compendial identity, purity, and limits for residual solvents and elemental impurities. The table below summarizes a representative release profile for a non-sterile milled grade; the sterile injectable grade adds bacterial endotoxin and particulate matter controls. Acceptance ranges are method-defined and should be confirmed against the current monograph and validated analytical procedure.

Assay by HPLC typically uses a buffered mobile phase with UV detection at a wavelength specific to the hydroxamic acid chromophore. Loss on drying is a critical release attribute because the mesylate salt is hygroscopic; even small moisture uptake reduces stoichiometric chelation efficiency per unit mass and can promote hydrolytic degradation during storage. The sterile injectable grade also undergoes container-closure integrity testing after filling and is shipped under nitrogen overlay in sealed aluminum-laminated overwrap.

For tablet and capsule dosage forms prepared from DFO-VET-API-MF, direct compression is performed on a rotary tablet press using a granulated excipient premix. Because the API is cohesive and moisture-sensitive, dry granulation by roller compaction with roll force 4–6 kN/cm and screen size 1.0 mm is preferred over wet granulation. When wet granulation is unavoidable, the binder is applied as a low-moisture aqueous solution in a fluid-bed granulator with inlet air temperature 25–35°C and dew point below 4°C; the use of a high-shear mixer with impeller speed above 200 rpm is not recommended because the water-soluble API can form hard agglomerates that reduce tablet disintegration. A glidant such as colloidal silicon dioxide at 0.5–1.5% w/w and a lubricant such as magnesium stearate at 0.25–1.0% w/w are added to the final blend. Flow is monitored by Carr index and Hausner ratio; batch release of tablets includes disintegration time ≤15 min in purified water at 37°C and assay of the active moiety using a stability-indicating HPLC method.

Roller compaction of the micronized API is carried out on a pharmaceutical roller compactor with roll diameter 200 mm and roll width 50 mm at gap 1.5–2.0 mm. The compacted ribbons are milled through a 1.0 mm screen to produce granules with a tapped density of 0.45–0.65 g/mL. This density range is important because denser granules reduce blend segregation but can delay tablet disintegration if the compaction force exceeds 8 kN/cm. Compression force on the tablet press is typically adjusted to produce tablet hardness 50–80 N for immediate-release tablets; higher hardness is used only when the formulation is intended for slower gastrointestinal binding. Dissolution testing is performed in 900 mL of purified water at 37±0.5°C with paddle speed 50 rpm using a stability-indicating HPLC method. A disintegration time of ≤15 min is specified for immediate-release batches, but this is a formulation-specific control rather than a compendial requirement for the API itself.

Injectable Solution Manufacture and Endotoxin Control

Injectable presentations require the DFO-VET-API-SL grade, which is released with a bacterial endotoxin limit of ≤0.50 EU/mg and processed in an ISO 14644-1 Class 5 cleanroom. The reconstituted solution is typically prepared at 100 mg/mL with Water for Injection and then filtered through a 0.22 µm sterilizing-grade membrane. Terminal steam sterilization is not recommended for the final solution because the hydroxamic acid groups are heat-labile; aseptic filtration is the standard method. The solution is filled into amber Type I glass vials under a nitrogen overlay to limit photodegradation and autoxidation.

One gram of deferoxamine mesylate theoretically binds 85 mg of elemental Fe³⁺ based on 1:1 molar stoichiometry and the molecular weight of 656.79 g/mol. This relationship is used in veterinary acute iron toxicity protocols to calculate the required mass of chelator relative to estimated absorbable iron. The injection should be diluted in 0.9% sodium chloride or 5% dextrose for intravenous infusion; rapid intravenous bolus administration is avoided because it has been associated with hypotension in human patients and is not routinely recommended in veterinary critical care. In-use hold time must be limited because the free ligand degrades at neutral to alkaline pH; pH of the reconstituted solution is controlled between 3.5 and 5.5 to improve short-term stability.

The sterile grade is dissolved in Water for Injection at 20–25°C with gentle agitation; high-shear mixing is avoided because foaming and cavitation accelerate oxidation. Filling is performed with a peristaltic or rotary piston pump into 10 mL or 50 mL Type I glass vials that are pre-sterilized by dry heat. The headspace oxygen content is reduced to <5% v/v by nitrogen flushing before stoppering. Finished vials are inspected for subvisible particles according to USP <790> and for container-closure integrity by vacuum decay or dye ingress. The osmolality of the compounded injection for intravenous use is adjusted with sodium chloride or dextrose; a typical intravenous infusion contains 10 mg/mL deferoxamine mesylate in 0.9% sodium chloride, but the final concentration is determined by the patient iron burden and fluid tolerance.

In medicated feed premixes and oral granules, the granular DFO-VET-API-GF grade is incorporated into a ribbon blender with a lactose monohydrate or dextrose carrier. Mixer validation requires a target homogeneity of ≤5.0% RSD across 10 sampling locations after 10–20 min of blending; the exact time is fixed by the validation protocol. Segregation is controlled by matching the particle size distribution of the carrier to the API granule fraction; a mean particle diameter D50 of 250–425 µm for the API granules reduces dust and improves flow into feed mills. Premix batches are filled into foil-lined bags with desiccant because the API is hygroscopic and oxygen-sensitive. The final feed incorporation rate must be calculated by a veterinarian from the iron burden or by the approved label; the API itself does not include a fixed feed concentration.

When the API Is Co-processed into Capsules, Powders, or Oral Solutions

For capsules and unit-dose powders, filling is performed in an environment maintained at 30–35% RH or lower to prevent sticking, hydrate uptake, and degradation. The powder is often blended with pregelatinized starch or mannitol; sucrose and other reducing sugars are avoided because they can participate in Maillard-type interactions with the secondary amine and hydroxamic acid structure under moisture and heat. Packaging is a cold-form foil laminate or an aluminum-laminated sachet with desiccant; residual moisture after packaging is verified by Karl Fischer titration to be ≤1.0%.

Oral solutions for gastrointestinal iron binding are compounded from the non-sterile micronized grade in purified water, with pH adjusted to 3.5–5.5 using citric acid or acetate buffer. The solution is dispensed in amber plastic or glass bottles and protected from light. Because aqueous deferoxamine mesylate undergoes autoxidation, long-term storage of compounded oral liquids is not recommended; any beyond-use dating must be supported by in-use stability data under VICH GL3 or equivalent. If a preservative is required, compatibility with the hydroxamic acid chelating site must be demonstrated; the API may bind trace metal ions from preservative systems and reduce its available chelating capacity.

Powder presentations for oral administration are filled into single-dose sachets under low humidity and often contain a dose of 500 mg deferoxamine mesylate per sachet. The powder is dissolved in water immediately before administration; the resulting solution has a slightly acidic pH of 3.5–5.5 and should be administered after gastric decontamination depending on the veterinary clinical presentation. The oral route is not a substitute for parenteral therapy once systemic iron absorption has occurred because deferoxamine mesylate is poorly absorbed across the intestinal epithelium.

Deferoxamine versus EDTA, Deferiprone, and Deferasirox in Veterinary Chelation

Deferoxamine mesylate differs from other chelating agents by its hexadentate coordination of Fe³⁺ and its low affinity for physiological calcium and magnesium. EDTA calcium disodium is a parenteral chelator with high calcium affinity; its veterinary use is primarily for lead intoxication, and inappropriate use in iron poisoning can produce hypocalcemia. Deferiprone and deferasirox are orally bioavailable synthetic chelators used in human iron overload, but their species-specific pharmacokinetic and safety profiles in companion animals are less documented. The following comparison is based on coordination chemistry and established product characteristics.

Deferoxamine’s hexadentate coordination has practical consequences. A single molecule wraps around the Fe³⁺ ion and forms a kinetically stable ferrioxamine complex; this contrasts with bidentate deferiprone, which requires three ligands and can transiently form incomplete complexes that may participate in redox cycling. The 1:1 stoichiometry also simplifies dose calculation for acute iron binding, because 1 g of deferoxamine mesylate binds 85 mg elemental iron. For veterinary acute iron toxicosis, deferoxamine mesylate remains the reference parenteral chelator because its ferrioxamine complex is excreted via the kidneys and bile, and because its low calcium-binding propensity reduces the risk of hypocalcemia relative to EDTA. The oral solid dosage forms are not interchangeable with systemic tablets of deferiprone or deferasirox; they are intended for gastrointestinal decontamination before systemic absorption. In feed premix applications, deferoxamine is not a growth supplement and should not be included in routine feed unless an iron burden or specific toxicological indication is documented.

Processing incompatibilities include strong oxidizing agents, ferric ion contamination from stainless-steel wear or iron-containing excipients, and alkaline buffer systems that accelerate hydroxamic acid degradation. Contact with trace metal ions produces the reddish ferrioxamine complex and should be interpreted as a loss of chelation capacity, not a product defect. The API should be stored in tightly closed, light-resistant containers at 20–25°C with excursions permitted only within 15–30°C, unless the manufacturer’s stability program justifies otherwise. For sterile grade, aseptic technique is mandatory; reconstituted solutions should not be pooled across vials for long-term storage, and any hold time must be validated under the intended clinical-use conditions.